≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

Diseases caused by chlamydiae

Endpoint Browser

AB1_CHLAMY_OTHER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — A74
  • Hospital discharge: ICD-9 — 07[6]
  • Hospital discharge: excluded ICD-9 — 0760A
  • Cause of death: ICD-10 — A74
  • Cause of death: ICD-9 — 07[6]
  • Cause of death: excluded ICD-9 — 0760A

2 out of 7 registries used, show all original rules.

414

4. Check minimum number of events

None

414

5. Include endpoints

None

414

6. Filter based on genotype QC (FinnGen only)

400

Control definitions (FinnGen only)

Control exclude
AB1_OTHER_CHLAMYDIAE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 400 350 50
Unadjusted period prevalence (%) 0.11 0.12 0.02
Median age at first event (years) 24.60 22.71 37.89

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
414
Matched controls
4140
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
0769C
ICD-9 Finland
Trachoma, unspecified[CHLAMYDIA ENDOMETRITIS ET SALPINGO-OOPHORITIS]
+∞
217.5
189
*
0769X
ICD-9 Finland
Trachoma, unspecified[CHLAMYDIA ALIA DEFINITA SEU NUD]
+∞
93.3
86
*
6350C
ICD-9 Finland
Legally induced abortion, Complicated by genital tract and pelvic infection[ABORTUS PROV LEGAL SINE COMPL,SOSIAALISET SYYT]
6.9
62.5
117
223
8513
FHL
Softening of cervix with abortifacient or laminars and associated surgical emptying of the uterus
8.2
47.7
69
98
H13.1*A74.0
ICD-10 Finland
Chlamydial conjunctivitis
+∞
42.4
40
*
A74.9
ICD-10 Finland
Chlamydial infection, unspecified
+∞
33.8
32
*
0769A
ICD-9 Finland
Trachoma, unspecified[CHLAMYDIA URETHRITIS]
+∞
32.7
31
*
6140A
ICD-9 Finland
Inflammatory disease of ovary, Fallopian tube, pelvic cellular tissue and peritoneum, Acute salpingitis and oophoritis[S-O-ITIS ACUTA]
11.9
28.8
30
27
8511
FHL
Cervical dilation and drainage with suction
4.7
22.6
56
132
0769D
ICD-9 Finland
Trachoma, unspecified[CHLAMYDIA PERIHEPATITIS]
+∞
18.9
18
*
7890A
ICD-9 Finland
Other symptoms involving abdomen and pelvis, Abdominal pain
3.4
12.8
48
152
A56.0
ICD-10 Finland
Chlamydial infection of lower genitourinary tract
5.5
9.7
19
36
N02AX02
ATC
tramadol; systemic, rectal
1.9
8.7
181
1213
A74.0
ICD-10 Finland
Chlamydial conjunctivitis
+∞
8.4
8
*
O04.9
ICD-10 Finland
Medical abortion, complete or unspecified, without complication
2.4
8.3
61
278
6421
FHL
Appendicectomy
3.0
8.2
38
137
EBA05
NOMESCO Finland
Complicated extraction of tooth
1.9
7.5
116
701
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.8
7.3
172
1181
8113
FHL
Fractional scraping
3.7
7.2
23
65
0981A
ICD-9 Finland
Gonococcal infections, Acute, of upper genito-urinary tract
30.6
7.2
9
*
Z04.9
ICD-10 Finland
Examination and observation for unspecified reason
3.5
6.9
24
72
P01AB01
ATC
metronidazole; oral, rectal
1.7
6.9
203
1482
A56.2
ICD-10 Finland
Chlamydial infection of genitourinary tract, unspecified
40.7
6.8
8
*
Z2446
NOMESCO Finland
Social worker
2.7
6.7
37
146
A74.8
ICD-10 Finland
Other chlamydial diseases
70.9
6.4
7
*
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
2.9
6.4
31
114
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
1.8
6.4
137
909
0980A
ICD-9 Finland
Gonococcal infections, Acute, of lower genito-urinary tract
+∞
6.3
6
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Ophthalmology
18 [38004463]
-7.4e-03
7.5e-01
3.6e+00
1.0e+50
2.8e+00
6.8e-01
-3.2e-02
cases:3.60%
controls:3.63%
cases:4.05%
controls:1.96%
cases:12.16%
controls:0.38%
cases:18.47%
controls:0.00%
cases:6.76%
controls:0.43%
cases:3.20%
controls:1.65%
cases:5.77%
controls:5.95%
8
76
214
2018
9
41
213
2053
27
8
195
2086
41
0
181
2094
15
9
207
2081
7
34
212
2027
12
115
196
1819
Laboratory Visit
OMOP4822461 [32036]
4.1e-02
2.0e-01
1.4e+00
3.6e+00
1.0e+00
2.8e-01
5.1e-02
cases:13.06%
controls:12.61%
cases:12.61%
controls:10.55%
cases:10.81%
controls:2.77%
cases:8.11%
controls:0.24%
cases:8.56%
controls:3.25%
cases:13.70%
controls:10.72%
cases:14.42%
controls:13.81%
29
264
193
1830
28
221
194
1873
24
58
198
2036
18
5
204
2089
19
68
203
2022
30
221
189
1840
30
267
178
1667
doxycycline; oral, parenteral
J01AA02 [21602800]
2.8e-01
7.8e-01
2.0e+00
—
3.0e+00
8.5e-01
3.2e-01
cases:10.36%
controls:8.02%
cases:9.01%
controls:4.35%
cases:3.60%
controls:0.53%
—
—
cases:7.21%
controls:0.38%
cases:10.96%
controls:5.00%
cases:25.00%
controls:19.54%
23
168
199
1926
20
91
202
2003
8
11
214
2083
—
16
8
206
2082
24
103
195
1958
52
378
156
1556
Emergency Room Visit
ER [9203]
4.4e-01
8.9e-01
3.3e+00
1.0e+50
1.7e+00
9.1e-01
6.7e-01
cases:16.67%
controls:11.46%
cases:11.71%
controls:5.16%
cases:13.51%
controls:0.57%
cases:10.36%
controls:0.00%
cases:3.15%
controls:0.57%
cases:10.96%
controls:4.71%
cases:27.40%
controls:16.18%
37
240
185
1854
26
108
196
1986
30
12
192
2082
23
0
199
2094
7
12
215
2078
24
97
195
1964
57
313
151
1621
Inpatient Visit
IP [9201]
4.0e-02
3.7e-01
2.2e+00
1.0e+50
1.7e+00
1.2e+00
5.7e-01
cases:27.48%
controls:26.70%
cases:8.56%
controls:6.06%
cases:5.41%
controls:0.62%
cases:39.64%
controls:0.00%
cases:3.60%
controls:0.67%
cases:14.61%
controls:4.80%
cases:12.50%
controls:7.50%
61
559
161
1535
19
127
203
1967
12
13
210
2081
88
0
134
2094
8
14
214
2076
32
99
187
1962
26
145
182
1789
Case Management Agency
251B00000X [38004193]
-2.3e-01
1.0e-01
8.8e-01
3.6e+00
4.7e-01
1.9e-01
3.2e-02
cases:22.07%
controls:26.36%
cases:18.92%
controls:17.38%
cases:14.86%
controls:6.78%
cases:10.81%
controls:0.33%
cases:10.81%
controls:7.03%
cases:21.92%
controls:18.87%
cases:25.48%
controls:24.87%
49
552
173
1542
42
364
180
1730
33
142
189
1952
24
7
198
2087
24
147
198
1943
48
389
171
1672
53
481
155
1453
Obstetrics / Gynecology
16 [38004461]
3.1e-01
3.0e-01
2.1e+00
—
9.8e-01
1.2e+00
8.8e-01
cases:25.23%
controls:19.91%
cases:9.01%
controls:6.83%
cases:9.01%
controls:1.15%
—
—
cases:3.60%
controls:1.39%
cases:21.92%
controls:7.81%
cases:47.60%
controls:27.30%
56
417
166
1677
20
143
202
1951
20
24
202
2070
—
8
29
214
2061
48
161
171
1900
99
528
109
1406
Pharmacy visit
OMOP4822462 [581458]
-4.0e-02
1.4e-01
7.6e-01
2.6e+00
8.7e-01
2.2e-01
1.3e-01
cases:46.85%
controls:47.85%
cases:47.75%
controls:44.17%
cases:28.38%
controls:15.62%
cases:10.36%
controls:0.86%
cases:31.53%
controls:16.22%
cases:56.16%
controls:50.66%
cases:87.02%
controls:85.42%
104
1002
118
1092
106
925
116
1169
63
327
159
1767
23
18
199
2076
70
339
152
1751
123
1044
96
1017
181
1652
27
282
metronidazole; oral, rectal
P01AB01 [21604857]
5.6e-01
1.6e+00
2.3e+00
—
—
1.2e+00
6.3e-01
cases:4.50%
controls:2.63%
cases:4.05%
controls:0.81%
cases:2.70%
controls:0.29%
—
—
—
—
cases:4.11%
controls:1.31%
cases:12.02%
controls:6.77%
10
55
212
2039
9
17
213
2077
6
6
216
2088
—
—
9
27
210
2034
25
131
183
1803
Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
21613-5 [3006093]
1.2e+00
2.2e+00
—
1.0e+50
—
1.7e+00
3.8e-01
cases:3.15%
controls:1.00%
cases:4.95%
controls:0.57%
—
—
cases:4.95%
controls:0.00%
—
—
cases:4.11%
controls:0.78%
cases:2.40%
controls:1.65%
7
21
215
2073
11
12
211
2082
—
11
0
211
2094
—
9
16
210
2045
5
32
203
1902
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
5.0e-01
1.8e+00
—
—
—
2.0e+00
8.3e-01
cases:4.50%
controls:2.77%
cases:4.50%
controls:0.76%
—
—
—
—
—
—
cases:6.85%
controls:0.97%
cases:5.29%
controls:2.38%
10
58
212
2036
10
16
212
2078
—
—
—
15
20
204
2041
11
46
197
1888
cefalexin; oral
J01DB01 [21602870]
3.1e-01
4.8e-01
1.6e+00
—
2.0e+00
3.3e-01
3.7e-01
cases:14.41%
controls:11.03%
cases:7.21%
controls:4.58%
cases:3.60%
controls:0.72%
—
—
cases:3.15%
controls:0.43%
cases:7.76%
controls:5.73%
cases:29.81%
controls:22.75%
32
231
190
1863
16
96
206
1998
8
15
214
2079
—
7
9
215
2081
17
118
202
1943
62
440
146
1494
Pain localized to other parts of lower abdomen
R10.3 [45534426]
4.9e-01
2.3e+00
—
—
—
1.3e+00
1.2e+00
cases:2.25%
controls:1.38%
cases:3.60%
controls:0.38%
—
—
—
—
—
—
cases:2.28%
controls:0.63%
cases:6.73%
controls:2.12%
5
29
217
2065
8
8
214
2086
—
—
—
5
13
214
2048
14
41
194
1893
Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
21416-3 [3003510]
6.6e-01
1.9e+00
—
—
—
1.5e+00
9.2e-01
cases:4.50%
controls:2.39%
cases:4.05%
controls:0.62%
—
—
—
—
—
—
cases:4.11%
controls:0.92%
cases:5.29%
controls:2.17%
10
50
212
2044
9
13
213
2081
—
—
—
9
19
210
2042
11
42
197
1892
azithromycin; oral, parenteral
J01FA10 [21602978]
2.2e-01
7.7e-01
—
1.0e+50
2.9e+00
5.2e-01
5.4e-01
cases:7.21%
controls:5.87%
cases:3.15%
controls:1.48%
—
—
cases:4.05%
controls:0.00%
cases:4.95%
controls:0.29%
cases:4.11%
controls:2.47%
cases:16.35%
controls:10.19%
16
123
206
1971
7
31
215
2063
—
9
0
213
2094
11
6
211
2084
9
51
210
2010
34
197
174
1737
Legally induced abortion, Complicated by genital tract and pelvic infection[ABORTUS PROV LEGAL SINE COMPL,SOSIAALISET SYYT]
6350C [2000404981]
1.1e+00
—
—
1.0e+50
—
2.6e+00
—
cases:3.15%
controls:1.05%
—
—
—
—
cases:10.81%
controls:0.00%
—
—
cases:3.65%
controls:0.29%
—
—
7
22
215
2072
—
—
24
0
198
2094
—
8
6
211
2055
—
Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
24111-7 [3011371]
9.8e-01
2.5e+00
—
1.0e+50
—
1.2e+00
6.7e-01
cases:2.25%
controls:0.86%
cases:4.95%
controls:0.43%
—
—
cases:4.05%
controls:0.00%
—
—
cases:2.28%
controls:0.68%
cases:2.40%
controls:1.24%
5
18
217
2076
11
9
211
2085
—
9
0
213
2094
—
5
14
214
2047
5
24
203
1910
General Practice
1 [38004446]
7.8e-01
1.0e+00
2.4e+00
1.0e+50
—
6.1e-01
7.1e-01
cases:6.76%
controls:3.20%
cases:4.50%
controls:1.67%
cases:2.70%
controls:0.24%
cases:2.25%
controls:0.00%
—
—
cases:2.74%
controls:1.50%
cases:8.17%
controls:4.19%
15
67
207
2027
10
35
212
2059
6
5
216
2089
5
0
217
2094
—
6
31
213
2030
17
81
191
1853
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
—
—
—
—
2.4e+00
8.2e-01
3.1e-01
—
—
—
—
—
—
—
—
cases:4.05%
controls:0.38%
cases:3.65%
controls:1.65%
cases:4.81%
controls:3.57%
—
—
—
—
9
8
213
2082
8
34
211
2027
10
69
198
1865
Basophils/Leukocytes in Blood
30180-4 [3022096]
-9.4e-02
2.8e-01
—
—
2.4e+00
1.2e+00
3.3e-01
cases:2.70%
controls:2.96%
cases:2.25%
controls:1.72%
—
—
—
—
cases:4.05%
controls:0.38%
cases:4.57%
controls:1.36%
cases:4.33%
controls:3.15%
6
62
216
2032
5
36
217
2058
—
—
9
8
213
2082
10
28
209
2033
9
61
199
1873
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
-9.4e-02
2.8e-01
—
—
2.4e+00
1.2e+00
3.5e-01
cases:2.70%
controls:2.96%
cases:2.25%
controls:1.72%
—
—
—
—
cases:4.05%
controls:0.38%
cases:4.57%
controls:1.36%
cases:4.33%
controls:3.10%
6
62
216
2032
5
36
217
2058
—
—
9
8
213
2082
10
28
209
2033
9
60
199
1874
Monocytes/Leukocytes in Blood
26485-3 [3019069]
-1.1e-01
2.8e-01
—
—
2.4e+00
1.2e+00
3.5e-01
cases:2.70%
controls:3.01%
cases:2.25%
controls:1.72%
—
—
—
—
cases:4.05%
controls:0.38%
cases:4.57%
controls:1.36%
cases:4.33%
controls:3.10%
6
63
216
2031
5
36
217
2058
—
—
9
8
213
2082
10
28
209
2033
9
60
199
1874
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
-1.9e-01
2.5e-01
—
—
2.4e+00
1.1e+00
2.5e-01
cases:2.70%
controls:3.25%
cases:2.25%
controls:1.77%
—
—
—
—
cases:4.05%
controls:0.38%
cases:4.57%
controls:1.60%
cases:4.33%
controls:3.41%
6
68
216
2026
5
37
217
2057
—
—
9
8
213
2082
10
33
209
2028
9
66
199
1868
Inpatient Hospital
21 [8717]
1.9e-01
1.6e-01
1.6e+00
1.0e+50
1.1e+00
4.5e-01
7.0e-01
cases:23.42%
controls:20.15%
cases:8.56%
controls:7.35%
cases:5.41%
controls:1.10%
cases:18.92%
controls:0.00%
cases:3.15%
controls:1.10%
cases:10.96%
controls:7.28%
cases:48.08%
controls:31.49%
52
422
170
1672
19
154
203
1940
12
23
210
2071
42
0
180
2094
7
23
215
2067
24
150
195
1911
100
609
108
1325
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
-9.4e-02
3.0e-01
—
—
2.3e+00
1.1e+00
1.4e-01
cases:2.70%
controls:2.96%
cases:2.25%
controls:1.67%
—
—
—
—
cases:3.60%
controls:0.38%
cases:4.57%
controls:1.55%
cases:3.85%
controls:3.36%
6
62
216
2032
5
35
217
2059
—
—
8
8
214
2082
10
32
209
2029
8
65
200
1869
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
7.0e-01
7.0e-01
2.3e+00
—
—
6.8e-01
6.2e-01
cases:7.21%
controls:3.72%
cases:4.05%
controls:2.05%
cases:3.15%
controls:0.33%
—
—
—
—
cases:3.20%
controls:1.65%
cases:7.69%
controls:4.29%
16
78
206
2016
9
43
213
2051
7
7
215
2087
—
—
7
34
212
2027
16
83
192
1851
methotrexate; oral, parenteral
L04AX03 [21603929]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.74%
controls:0.29%
—
—
—
—
—
—
—
6
6
213
2055
—
methotrexate
L01BA01 [21601423]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:2.74%
controls:0.29%
—
—
—
—
—
—
—
6
6
213
2055
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
-3.1e-01
2.5e-01
—
—
2.2e+00
1.1e+00
3.7e-01
cases:2.25%
controls:3.06%
cases:2.25%
controls:1.77%
—
—
—
—
cases:3.60%
controls:0.43%
cases:4.11%
controls:1.46%
cases:4.81%
controls:3.36%
5
64
217
2030
5
37
217
2057
—
—
8
9
214
2081
9
30
210
2031
10
65
198
1869
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
-9.0e-02
3.5e-01
—
—
2.2e+00
7.7e-01
2.6e-01
cases:3.15%
controls:3.44%
cases:2.70%
controls:1.91%
—
—
—
—
cases:3.60%
controls:0.43%
cases:4.11%
controls:1.94%
cases:5.29%
controls:4.14%
7
72
215
2022
6
40
216
2054
—
—
8
9
214
2081
9
40
210
2021
11
80
197
1854
Basophils [#/volume] in Blood
26444-0 [3006315]
-3.3e-01
2.5e-01
—
—
2.2e+00
1.1e+00
3.7e-01
cases:2.25%
controls:3.10%
cases:2.25%
controls:1.77%
—
—
—
—
cases:3.60%
controls:0.43%
cases:4.11%
controls:1.46%
cases:4.81%
controls:3.36%
5
65
217
2029
5
37
217
2057
—
—
8
9
214
2081
9
30
210
2031
10
65
198
1869
Eosinophils [#/volume] in Blood
26449-9 [3013115]
-3.6e-01
2.5e-01
—
—
2.2e+00
1.1e+00
3.6e-01
cases:2.25%
controls:3.20%
cases:2.25%
controls:1.77%
—
—
—
—
cases:3.60%
controls:0.43%
cases:4.11%
controls:1.46%
cases:4.81%
controls:3.41%
5
67
217
2027
5
37
217
2057
—
—
8
9
214
2081
9
30
210
2031
10
66
198
1868
Outpatient Hospital
22 [8756]
4.0e-01
4.5e-01
2.1e+00
1.0e+50
—
4.1e-01
5.1e-01
cases:10.36%
controls:7.21%
cases:4.50%
controls:2.91%
cases:3.15%
controls:0.38%
cases:4.95%
controls:0.00%
—
—
cases:5.02%
controls:3.40%
cases:27.88%
controls:18.87%
23
151
199
1943
10
61
212
2033
7
8
215
2086
11
0
211
2094
—
11
70
208
1991
58
365
150
1569
Outpatient Visit
OP [9202]
3.9e-01
1.0e-01
1.1e+00
—
8.9e-01
4.7e-01
2.4e-01
cases:45.05%
controls:35.72%
cases:20.27%
controls:18.67%
cases:10.81%
controls:3.96%
—
—
cases:9.91%
controls:4.31%
cases:27.85%
controls:19.51%
cases:48.56%
controls:42.55%
100
748
122
1346
45
391
177
1703
24
83
198
2011
—
22
90
200
2000
61
402
158
1659
101
823
107
1111
temazepam; oral
N05CD07 [21604642]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.81%
controls:0.78%
—
—
—
—
—
—
10
15
198
1919
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
5.9e-01
—
—
—
—
1.8e+00
4.7e-01
cases:3.15%
controls:1.77%
—
—
—
—
—
—
—
—
cases:3.20%
controls:0.53%
cases:4.81%
controls:3.05%
7
37
215
2057
—
—
—
—
7
11
212
2050
10
59
198
1875
Appendicectomy
6421 [2000100987]
1.8e+00
-1.0e+50
—
—
—
—
—
cases:3.60%
controls:0.62%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
8
13
214
2081
0
5
222
2089
—
—
—
—
—
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
2.7e-01
1.7e-01
—
—
1.7e+00
8.0e-01
4.7e-02
cases:5.86%
controls:4.54%
cases:3.15%
controls:2.67%
—
—
—
—
cases:3.60%
controls:0.67%
cases:5.02%
controls:2.33%
cases:4.33%
controls:4.14%
13
95
209
1999
7
56
215
2038
—
—
8
14
214
2076
11
48
208
2013
9
80
199
1854
methylprednisolone; oral, parenteral
H02AB04 [21602732]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:4.33%
controls:0.88%
—
0
5
222
2089
—
—
—
—
9
17
199
1917
Rheumatology
66 [38004491]
—
—
—
—
—
1.2e+00
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:2.28%
controls:0.68%
cases:4.33%
controls:0.88%
—
—
—
—
—
5
14
214
2047
9
17
199
1917
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.9e-01
2.4e-01
1.1e+00
—
1.5e+00
1.7e-01
4.2e-02
cases:9.91%
controls:7.59%
cases:7.21%
controls:5.78%
cases:3.15%
controls:1.10%
—
—
cases:4.95%
controls:1.20%
cases:5.94%
controls:5.05%
cases:9.62%
controls:9.26%
22
159
200
1935
16
121
206
1973
7
23
215
2071
—
11
25
211
2065
13
104
206
1957
20
179
188
1755
Delivery in a completely normal case[PARTUS SINE COMPLICATIONE]
6500B [2000405100]
2.8e-01
—
—
—
—
8.2e-01
1.4e+00
cases:7.21%
controls:5.54%
—
—
—
—
—
—
—
—
cases:2.28%
controls:1.02%
cases:11.54%
controls:3.00%
16
116
206
1978
—
—
—
—
5
21
214
2040
24
58
184
1876
Medical abortion, complete or unspecified, without complication
O04.9 [45543909]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:1.45%
—
—
—
—
—
—
12
28
196
1906
lansoprazole; oral
A02BC03 [21600098]
—
—
—
—
—
-1.0e+50
1.4e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:5.77%
controls:1.55%
—
—
—
—
—
0
8
219
2053
12
30
196
1904
Other and unspecified abdominal pain
R10.4 [45568113]
8.9e-01
1.3e+00
—
—
—
—
1.3e+00
cases:5.41%
controls:2.29%
cases:2.25%
controls:0.62%
—
—
—
—
—
—
—
—
cases:9.13%
controls:2.59%
12
48
210
2046
5
13
217
2081
—
—
—
—
19
50
189
1884
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
6.3e-01
1.5e+00
—
1.0e+50
—
1.3e+00
-2.1e-01
cases:3.60%
controls:1.96%
cases:3.60%
controls:0.86%
—
—
cases:4.05%
controls:0.00%
—
—
cases:5.02%
controls:1.41%
cases:2.40%
controls:2.95%
8
41
214
2053
8
18
214
2076
—
9
0
213
2094
—
11
29
208
2032
5
57
203
1877
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
—
9.2e-01
—
—
—
—
1.3e+00
—
—
cases:2.25%
controls:0.91%
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.86%
—
5
19
217
2075
—
—
—
—
13
36
195
1898
Pulmonary Disease
29 [38004472]
1.7e-01
8.7e-01
—
1.0e+50
—
1.3e+00
1.2e+00
cases:2.70%
controls:2.29%
cases:2.25%
controls:0.96%
—
—
cases:3.60%
controls:0.00%
—
—
cases:3.65%
controls:1.02%
cases:6.25%
controls:2.02%
6
48
216
2046
5
20
217
2074
—
8
0
214
2094
—
8
21
211
2040
13
39
195
1895
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
-2.6e-01
—
—
—
-1.0e+50
1.1e+00
1.5e-01
cases:4.50%
controls:5.78%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:6.85%
controls:2.38%
cases:6.25%
controls:5.43%
10
121
212
1973
—
—
—
0
10
222
2080
15
49
204
2012
13
105
195
1829
Otolaryngology
4 [38004449]
9.3e-01
1.2e+00
—
—
—
1.4e+00
2.4e-01
cases:10.81%
controls:4.58%
cases:4.05%
controls:1.29%
—
—
—
—
—
—
cases:3.20%
controls:0.78%
cases:5.77%
controls:4.60%
24
96
198
1998
9
27
213
2067
—
—
—
7
16
212
2045
12
89
196
1845
Internal Medicine
11 [38004456]
3.6e-01
3.6e-01
1.1e+00
1.0e+50
9.2e-01
8.5e-01
3.6e-01
cases:12.16%
controls:8.79%
cases:6.31%
controls:4.49%
cases:2.25%
controls:0.76%
cases:10.81%
controls:0.00%
cases:2.25%
controls:0.91%
cases:10.50%
controls:4.75%
cases:18.75%
controls:13.86%
27
184
195
1910
14
94
208
2000
5
16
217
2078
24
0
198
2094
5
19
217
2071
23
98
196
1963
39
268
169
1666
General Surgery
2 [38004447]
5.1e-01
5.9e-01
1.6e+00
1.0e+50
—
4.2e-01
7.1e-01
cases:15.32%
controls:9.84%
cases:6.31%
controls:3.58%
cases:2.25%
controls:0.48%
cases:2.70%
controls:0.00%
—
—
cases:4.57%
controls:3.06%
cases:22.12%
controls:12.20%
34
206
188
1888
14
75
208
2019
5
10
217
2084
6
0
216
2094
—
10
63
209
1998
46
236
162
1698
Outcome of delivery
Z37 [45581024]
1.3e-01
—
—
—
—
-1.6e-01
6.1e-01
cases:13.96%
controls:12.51%
—
—
—
—
—
—
—
—
cases:3.20%
controls:3.74%
cases:27.40%
controls:16.96%
31
262
191
1832
—
—
—
—
7
77
212
1984
57
328
151
1606
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
2.3e-01
—
—
—
—
—
7.1e-01
cases:2.70%
controls:2.15%
—
—
—
—
—
—
—
—
—
—
cases:7.21%
controls:3.67%
6
45
216
2049
—
—
—
—
—
15
71
193
1863
piroxicam; ointment
M02AA07 [21604043]
6.9e-01
-1.0e+50
—
—
—
—
-7.4e-03
cases:2.25%
controls:1.15%
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
cases:5.29%
controls:5.33%
5
24
217
2070
0
13
222
2081
—
—
—
—
11
103
197
1831
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
0
6
222
2088
—
—
—
—
0
14
208
1920
ramipril; oral
C09AA05 [21601789]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2085
—
—
—
—
—
clopidogrel; oral
B01AC04 [21600989]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
0
6
222
2088
0
6
222
2088
—
—
—
0
5
219
2056
—
Intravenous general anesthesia
WX404 [2001310807]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
Crohn disease of small intestine
K50.0 [45596324]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Venous insufficiency (chronic)(peripheral)
I87.2 [45552867]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
0
7
222
2087
—
—
—
—
0
5
208
1929
Cells panel - Urine sediment
58434-2 [40761535]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2087
—
—
—
—
—
—
Chronic hypertension
205 [2001600203]
5.7e-01
—
—
—
—
-1.0e+50
—
cases:2.25%
controls:1.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
5
27
217
2067
—
—
—
—
0
6
219
2055
—
Prostate specific Ag [Mass/volume] in Serum or Plasma
2857-1 [3013603]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
0
5
222
2085
—
—
Supervision of other normal pregnancy
Z34.8 [45537628]
—
-1.0e+50
—
—
—
-1.0e+50
8.2e-01
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:4.81%
controls:2.17%
—
0
9
222
2085
—
—
—
0
6
219
2055
10
42
198
1892
Phase of life problem adult
P25 [2002000820]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
219
2056
—
scopolamine
A04AD01 [21600499]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
11
208
1923
Cesarean section
8811 [2000101397]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.44%
cases:0.00%
controls:1.40%
—
0
11
222
2083
—
—
—
0
9
219
2052
0
27
208
1907
Cervical spine MRI examination with high intensity magnet
NA1BG [2001306990]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
—
—
—
-1.0e+50
—
-6.0e-02
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:3.37%
controls:3.57%
—
—
—
—
0
5
222
2085
—
7
69
201
1865
Obesity
E66 [45547648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Other extensive ultrasound examination of artery
PG1DE [2001309713]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
One-surface restoration
SFA10 [2001310358]
-5.6e-01
—
—
—
—
—
-5.3e-02
cases:2.70%
controls:4.63%
—
—
—
—
—
—
—
—
—
—
cases:4.33%
controls:4.55%
6
97
216
1997
—
—
—
—
—
9
88
199
1846
tetracycline; oral, parenteral
J01AA07 [21602805]
—
-1.0e+50
—
—
—
—
9.2e-02
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
cases:2.88%
controls:2.64%
—
0
12
222
2082
—
—
—
—
6
51
202
1883
chlorhexidine
D09AA12 [21602275]
1.1e+00
—
—
—
—
-1.0e+50
—
cases:3.15%
controls:1.05%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
7
22
215
2072
—
—
—
—
0
8
219
2053
—
atorvastatin; oral
C10AA05 [21601860]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
0
15
222
2079
0
6
222
2088
—
—
—
—
Scheduled procedure
ZXD10 [2001311387]
1.0e+00
—
—
—
—
—
9.3e-01
cases:3.15%
controls:1.15%
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:1.55%
7
24
215
2070
—
—
—
—
—
8
30
200
1904
formoterol and budesonide
R03AK07 [21603281]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2087
—
—
—
—
—
—
Medical doctor
Z2221 [2001311556]
7.9e-01
—
—
—
—
—
9.3e-01
cases:3.60%
controls:1.67%
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:1.55%
8
35
214
2059
—
—
—
—
—
8
30
200
1904
dexbrompheniramine, combinations
R06AB56 [21603469]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
11
208
1923
Bicarbonate [Moles/volume] standard in Venous blood
19232-8 [3007628]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: quitter
SMOKING-2-2-3 [2002330111]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2085
—
—
—
—
—
—
Low back symptom/complaint
L03 [2002000628]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.98%
—
0
9
222
2085
—
—
—
—
8
19
200
1915
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
Other obstetric ultrasound examination
MA2XE [2001306838]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
8
222
2086
0
5
222
2089
—
—
—
—
—
ketoprofen; ointment
M02AA10 [21604046]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.67%
—
—
—
—
—
—
5
13
203
1921
salbutamol; oral, parenteral
R03CC02 [21603312]
—
—
—
—
—
—
5.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.33%
controls:2.59%
—
—
—
—
—
—
9
50
199
1884
Tissue transglutaminase IgG Ab [Units/volume] in Serum
32998-7 [3046870]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay
97097-0 [36033641]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
dexrabeprazole
A02BC07 [45893509]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.36%
—
—
—
—
—
0
5
219
2056
0
7
208
1927
Two-surface restoration
SFA20 [2001310359]
2.8e-01
—
-1.0e+50
—
—
6.8e-01
3.4e-02
cases:6.31%
controls:4.82%
—
—
cases:0.00%
controls:0.24%
—
—
—
—
cases:2.28%
controls:1.16%
cases:5.29%
controls:5.12%
14
101
208
1993
—
0
5
222
2089
—
—
5
24
214
2037
11
99
197
1835
norfloxacin; oral
J01MA06 [21603013]
—
-1.0e+50
—
—
—
—
2.2e-01
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:2.88%
controls:2.33%
—
0
9
222
2085
—
—
—
—
6
45
202
1889
Moderate depressive episode
F32.1 [45552478]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
8
208
1926
Diabetes mellitus, Diabetes with hyperosmolarity[COMA DIABETICUM ,TYYPPI I]
2502B [2000402303]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2085
—
—
—
—
—
—
Screening procedure
SPAT1324 [2001700425]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
219
2056
—
antibiotics in combination with corticosteroids
D01AA20 [21601918]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
9
219
2052
—
Acute sinusitis
J01 [45548098]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
0
5
222
2089
—
—
—
—
—
0
9
208
1925
Recurrent depressive disorder, unspecified
F33.9 [45581458]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Persistent ostium secundum
Q21.10 [2000503270]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Ultrasound examination of uterus and parametria
LC2AE [2001306543]
1.0e+00
—
—
—
—
—
—
cases:2.25%
controls:0.81%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
217
2077
—
—
—
—
—
—
betamethasone
A07EA04 [21600656]
5.5e-01
—
—
—
—
-1.0e+50
1.5e-02
cases:2.70%
controls:1.58%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:2.88%
controls:2.84%
6
33
216
2061
—
—
—
—
0
12
219
2049
6
55
202
1879
Knee symptom/complaint
L15 [2002000639]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
219
2056
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
1.0e+00
—
—
—
—
—
—
cases:2.70%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
6
21
216
2073
—
—
—
—
—
—
olanzapine; oral, parenteral
N05AH03 [21604543]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
6
219
2055
—
triamcinolone and antiseptics
D07BB03 [21602150]
1.0e+00
—
—
—
—
-1.0e+50
—
cases:3.15%
controls:1.15%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
7
24
215
2070
—
—
—
—
0
8
219
2053
—
Pure hypercholesterolaemia
E78.0 [45542771]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
0
6
222
2088
—
—
—
—
—
0
12
208
1922
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
amitriptyline and psycholeptics
N06CA01 [21604789]
—
—
—
—
—
—
9.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.93%
—
—
—
—
—
—
5
18
203
1916
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
4.7e-01
3.1e-01
—
—
—
6.4e-01
1.8e-01
cases:12.61%
controls:8.26%
cases:4.05%
controls:3.01%
—
—
—
—
—
—
cases:6.85%
controls:3.74%
cases:16.83%
controls:14.48%
28
173
194
1921
9
63
213
2031
—
—
—
15
77
204
1984
35
280
173
1654
erythromycin; oral, parenteral
J01FA01 [21602970]
—
—
—
—
—
—
1.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:3.05%
—
—
—
—
—
—
7
59
201
1875
Hyaline casts [#/volume] in Urine by Automated count
51484-4 [3030981]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
8
208
1926
etonogestrel; implant
G03AC08 [21602504]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
208
1927
Lipid panel - Serum or Plasma
100898-6 [1761868]
4.1e-01
—
—
—
-1.0e+50
—
—
cases:2.70%
controls:1.81%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
6
38
216
2056
—
—
—
0
5
222
2085
—
—
lovastatin; oral
C10AA02 [21601857]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
amitriptyline; oral, parenteral
N06AA09 [21604696]
—
—
—
—
-1.0e+50
-1.0e+50
6.3e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.34%
cases:2.40%
controls:1.29%
—
—
—
—
0
5
222
2085
0
7
219
2054
5
25
203
1909
Varicose veins of lower extremities, Other and unspecified, without ulcer
45499 [2000302752]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
progesterone; oral, parenteral, rectal, vaginal
G03DA04 [21602542]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
—
—
—
—
0
7
219
2054
—
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
—
—
—
—
—
-1.0e+50
6.3e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:2.40%
controls:1.29%
—
—
—
—
—
0
14
219
2047
5
25
203
1909
Contact with and exposure to other communicable diseases
Z20.8 [45542410]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
9
208
1925
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.36%
—
—
—
—
—
0
5
219
2056
0
7
208
1927
Trachoma, unspecified[CHLAMYDIA PERIHEPATITIS]
0769D [2000400642]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:4.05%
controls:0.00%
—
—
—
—
—
—
—
—
—
9
0
213
2094
—
—
—
MCH [Entitic mass]
28539-5 [3035941]
8.3e-02
1.8e-01
7.9e-01
—
8.9e-01
2.1e-01
-5.2e-02
cases:11.26%
controls:10.46%
cases:9.01%
controls:7.64%
cases:3.60%
controls:1.67%
—
—
cases:4.95%
controls:2.11%
cases:8.68%
controls:7.18%
cases:11.06%
controls:11.58%
25
219
197
1875
20
160
202
1934
8
35
214
2059
—
11
44
211
2046
19
148
200
1913
23
224
185
1710
External hemorrhoids without complication
I84.5 [45581832]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
0
8
219
2053
—
Removal of sutures from oral mucosa
SXB00 [2001310580]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.26%
0
5
222
2089
—
—
—
—
0
5
219
2056
0
5
208
1929
Colonoscopy Study observation
28023-0 [3022145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
222
2084
—
—
—
—
—
—
Estradiol (E2) [Moles/volume] in Serum or Plasma
14715-7 [3026725]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
ambroxol; oral
R05CB06 [21603385]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2087
—
—
—
—
—
—
Other complicated root filling
SGB30 [2001310390]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
2.6e-02
6.9e-01
—
—
—
—
2.2e-01
cases:2.25%
controls:2.20%
cases:2.25%
controls:1.15%
—
—
—
—
—
—
—
—
cases:4.81%
controls:3.88%
5
46
217
2048
5
24
217
2070
—
—
—
—
10
75
198
1859
Leiomyoma of uterus, unspecified
D25.9 [45542693]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Electrophysiological examination of eye
XCD10 [2001300413]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Bacteria identified in Isolate by Culture
43409-2 [3042936]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
azelastine; nasal
R01AC03 [21605035]
1.0e+00
—
—
—
—
—
—
cases:2.70%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
—
—
6
21
216
2073
—
—
—
—
—
—
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
—
-1.0e+50
—
—
—
—
5.0e-01
—
—
cases:0.00%
controls:0.86%
—
—
—
—
—
—
—
—
cases:3.85%
controls:2.38%
—
0
18
222
2076
—
—
—
—
8
46
200
1888
Diabetes mellitus, Diabetes with renal manifestations[DIABETES MELLITUS CUM COMPLICATIONE OCULI ,TYYPPI I]
2504B [2000402311]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
222
2086
—
—
—
—
—
—
roxithromycin; oral
J01FA06 [21602974]
7.0e-01
1.7e+00
—
—
—
1.1e+00
6.4e-01
cases:4.50%
controls:2.29%
cases:2.70%
controls:0.53%
—
—
—
—
—
—
cases:2.28%
controls:0.78%
cases:10.10%
controls:5.58%
10
48
212
2046
6
11
216
2083
—
—
—
5
16
214
2045
21
108
187
1826
Pain general/multiple sites
A01 [2002000142]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Peritonsillar abscess
J36 [45581858]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Maternal care for (suspected) chromosomal abnormality in fetus
O35.1 [45606585]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Carboxyhemoglobin/Hemoglobin.total in Blood
20563-3 [3023081]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Fluoride application or other respective small prophylactic procedure
SCC01 [2001310310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Mouth breathing
R06.5 [45573006]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Very demanding periodontal treatment
SDA05 [2001310330]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Secondary amenorrhoea
N91.1 [45601758]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
Open wound of finger(s) with damage to nail
S61.1 [45578758]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Shoulder symptom/complaint
L08 [2002000632]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
Localized swelling, mass and lump, unspecified
R22.9 [45577788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
podophyllotoxin
D06BB04 [21602086]
—
-1.0e+50
—
—
—
-1.0e+50
4.3e-01
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
cases:0.00%
controls:0.58%
cases:3.85%
controls:2.53%
—
0
7
222
2087
—
—
—
0
12
219
2049
8
49
200
1885
pH of Blood
11558-4 [3010421]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Acute bronchitis
J20 [45581849]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
Extensive health check-up of expecting family
SPAT1197 [2001700298]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
0
10
222
2084
—
—
—
—
—
clidinium and psycholeptics
A03CA02 [21600204]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2087
—
—
—
—
—
—
erdosteine; oral
R05CB15 [21603394]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
10
208
1924
Acute pharyngitis
J02 [45557615]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Acute and subacute iridocyclitis
H20.0 [45542994]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Delivery by emergency caesarean section
O82.10 [2000503217]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.34%
—
—
—
0
6
222
2088
—
—
—
0
7
219
2054
—
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
0
15
222
2079
0
7
222
2087
—
—
—
—
—
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2087
—
—
—
—
—
Acute bronchitis, unspecified
J20.9 [45562445]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
222
2084
—
—
—
—
—
—
naproxen and misoprostol
M01AE56 [40254098]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
phenylephrine, combinations
R01BA53 [21603214]
2.8e-01
—
—
—
—
—
-7.5e-02
cases:2.25%
controls:1.72%
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:3.10%
5
36
217
2058
—
—
—
—
—
6
60
202
1874
valaciclovir; oral
J05AB11 [21603137]
2.1e+00
—
—
—
—
—
1.6e+00
cases:2.25%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:0.67%
5
6
217
2088
—
—
—
—
—
7
13
201
1921
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
10
222
2084
0
5
222
2089
—
—
—
—
0
5
208
1929
intermediate-acting sulfonamides - combinations
J01EC20 [21602948]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:2.53%
—
—
—
—
—
—
6
49
202
1885
nortriptyline; oral, parenteral
N06AA10 [21604697]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
6
222
2088
—
—
—
—
—
0
7
208
1927
Cystitis/urinary infection other
U71 [2002001191]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
208
1927
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
6.8e-01
1.3e+00
—
1.0e+50
—
1.3e+00
1.1e+00
cases:3.15%
controls:1.62%
cases:2.70%
controls:0.72%
—
—
cases:2.25%
controls:0.00%
—
—
cases:2.28%
controls:0.63%
cases:4.81%
controls:1.65%
7
34
215
2060
6
15
216
2079
—
5
0
217
2094
—
5
13
214
2048
10
32
198
1902
Medical Oncology
90 [38004507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
0
13
208
1921
Diabetes mellitus, Diabetes with ketoacidosis[DIABETES MELLITUS CUM KETOACIDOSI ,TYYPPI I]
2501B [2000402299]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
10
222
2084
—
—
—
—
—
0
8
208
1926
clindamycin; vaginal
G01AA10 [21602372]
—
—
—
—
—
—
1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.33%
controls:3.62%
—
—
—
—
—
—
9
70
199
1864
Hearing complaint
H02 [2002000476]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
cefaclor; oral
J01DC04 [21602886]
—
—
—
—
—
—
9.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.98%
—
—
—
—
—
—
5
19
203
1915
Normal pregnancy, Supervision of normal first pregnancy
V220A [2000409175]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
6
222
2088
—
—
—
—
—
0
10
208
1924
cromoglicic acid
S01GX01 [21605085]
6.1e-01
—
—
—
—
—
5.8e-01
cases:2.70%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
cases:5.77%
controls:3.31%
6
31
216
2063
—
—
—
—
—
12
64
196
1870
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
0
6
222
2088
—
—
—
—
0
10
208
1924
Sexual health counselling
SPAT1308 [2001700409]
1.9e-01
—
—
—
—
—
9.4e-01
cases:2.70%
controls:2.24%
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:1.34%
6
47
216
2047
—
—
—
—
—
7
26
201
1908
Anxiety disorder/anxiety state
P74 [2002000868]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.47%
0
7
222
2087
—
—
—
—
0
5
219
2056
0
9
208
1925
False labour before 37 completed weeks of gestation
O47.0 [45582556]
—
-1.0e+50
—
—
—
—
8.3e-01
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:3.37%
controls:1.50%
—
0
5
222
2089
—
—
—
—
7
29
201
1905
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
—
—
—
—
-1.0e+50
2.7e-02
-4.7e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
cases:2.74%
controls:2.67%
cases:2.40%
controls:3.77%
—
—
—
—
0
21
222
2069
6
55
213
2006
5
73
203
1861
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
6
222
2088
—
—
—
—
—
0
6
208
1928
Delivery by elective caesarean section
O82.0 [45548833]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
mirtazapine; oral
N06AX11 [21604740]
9.2e-01
—
—
—
—
—
1.2e+00
cases:2.70%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
cases:5.29%
controls:1.71%
6
23
216
2071
—
—
—
—
—
11
33
197
1901
Root filling of tooth with one root canal
SGB10 [2001310388]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
aciclovir
D06BB03 [21602085]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Standard cardiac ultrasound examination
FM1AE [2001303278]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
222
2083
—
—
—
—
—
—
Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma
14928-6 [3026989]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
tacrolimus
D11AH01 [21602338]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
0
9
222
2085
—
—
—
—
—
0
5
208
1929
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
—
—
—
—
—
—
1.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:2.07%
—
—
—
—
—
—
5
40
203
1894
Perimetry
XCK00 [2001301380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Base excess in Venous blood by calculation
1927-3 [3002032]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
cases:0.00%
controls:0.47%
—
0
9
222
2085
—
—
—
0
5
219
2056
0
9
208
1925
insulin (beef); parenteral
A10AD02 [21600730]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
222
2088
—
0
8
222
2082
—
—
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
—
—
—
—
—
2.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:2.38%
—
—
—
—
—
—
6
46
202
1888
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:0.47%
—
—
—
—
—
—
5
9
203
1925
terbinafine; oral
D01BA02 [21601967]
—
-1.0e+50
—
—
—
—
1.0e+00
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:2.88%
controls:1.03%
—
0
7
222
2087
—
—
—
—
6
20
202
1914
terbinafine; ointment
D01AE15 [21601954]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
0
5
222
2089
—
—
—
—
0
6
208
1928
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
covid-19, RNA-based vaccine
J07BN01 [954934]
5.0e-02
3.5e-01
—
—
—
—
-5.5e-02
cases:5.41%
controls:5.16%
cases:2.70%
controls:1.91%
—
—
—
—
—
—
—
—
cases:4.81%
controls:5.07%
12
108
210
1986
6
40
216
2054
—
—
—
—
10
98
198
1836
Fungus identified in Specimen by Culture
580-1 [3000494]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method
30522-7 [3010156]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
5
222
2089
—
—
—
—
—
0
8
208
1926
Plastic And Reconstructive Surgery
24 [38004467]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
0
9
222
2085
—
—
—
0
11
219
2050
—
Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
5253-0 [3027545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
222
2086
—
—
—
—
—
—
Diabetes insulin dependent
T89 [2002001130]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
Respiratory infection other
R83 [2002000951]
1.5e-01
—
—
—
—
—
1.8e-01
cases:2.70%
controls:2.34%
—
—
—
—
—
—
—
—
—
—
cases:2.40%
controls:2.02%
6
49
216
2045
—
—
—
—
—
5
39
203
1895
Vomiting of pregnancy, unspecified
O21.9 [45577562]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Premature rupture of membranes, unspecified
O42.9 [45558306]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
222
2086
—
—
—
—
—
—
Panic disorder [episodic paroxysmal anxiety]
F41.0 [45562047]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
Hemorrhoidectomy
JHB00 [2001305139]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
0
8
208
1926
Supervision of pregnancy with other poor reproductive or obstetric history
Z35.2 [45585822]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
0
13
222
2081
0
5
222
2089
—
—
—
—
—
Prolonged first stage (of labour)
O63.0 [45563158]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
219
2056
—
Legally induced abortion, With unspecified complication[ABORT PROV LEGAL CUM COMPL AL,SOSIAALISET SYYT]
6358C [2000404991]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Functional dyspepsia
K30 [45591584]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
Urinary frequency/urgency
U02 [2002001138]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
0
5
222
2089
—
—
—
0
5
219
2056
—
Acute upper respiratory infections of multiple and unspecified sites
J06 [45601116]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
ofloxacin
S01AE01 [43534856]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
208
1927
Left side
ZXA05 [2001311347]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
12
208
1922
Antepartum dilatation of cervical canal
MAC10 [2001306871]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: occasional
SMOKING-1-1-2 [2002330117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2085
—
—
—
—
—
—
Gestational [pregnancy-induced] hypertension
O13 [45539091]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Benign neoplasm: Pituitary gland
D35.2 [45581304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
enalapril; oral, parenteral
C09AA02 [21601786]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
0
5
222
2089
—
—
0
21
219
2040
—
Cholesterol non HDL [Moles/volume] in Serum or Plasma
70204-3 [42868678]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.72%
0
5
222
2089
—
—
—
—
0
6
219
2055
0
14
208
1920
Antenatal screening for fetal growth retardation
717801000 [36713463]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
208
1927
astemizole; oral
R06AX11 [21603512]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
cases:0.00%
controls:0.72%
—
—
—
—
—
0
6
219
2055
0
14
208
1920
dexamethasone
D07AB19 [21602116]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Arthroscopy
1220 [2000100102]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
0
12
208
1922
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
0
5
219
2056
—
Eye discharge
F03 [2002000401]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
Contraceptive management, Sterilisation
V252A [2000409180]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
0
15
222
2079
0
6
222
2088
—
—
—
—
—
Medical examin/health eval complete
-30 [2002000101]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2085
—
—
—
—
—
—
Bicarbonate [Moles/volume] standard in Arterial blood
19230-2 [3014218]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
-4.3e-02
—
-1.0e+50
—
—
—
-3.9e-03
cases:2.70%
controls:2.82%
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:2.88%
controls:2.90%
6
59
216
2035
—
0
9
222
2085
—
—
—
6
56
202
1878
Follitropin [Units/volume] in Serum or Plasma by Immunoassay
83098-4 [42529215]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Differential panel, method unspecified - Blood
69738-3 [42870588]
3.3e-01
5.7e-01
—
—
—
1.3e+00
3.9e-01
cases:2.70%
controls:1.96%
cases:2.25%
controls:1.29%
—
—
—
—
—
—
cases:4.11%
controls:1.12%
cases:2.88%
controls:1.96%
6
41
216
2053
5
27
217
2067
—
—
—
9
23
210
2038
6
38
202
1896
Depressive episode, unspecified
F32.9 [45571760]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:0.67%
—
—
—
—
—
—
6
13
202
1921
SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
94759-8 [586526]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Cutaneous abscess, furuncle and carbuncle of trunk
L02.2 [45586751]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
scopolamine, combinations
A04AD51 [21600507]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
11
208
1923
Single live birth
Z37.0 [45571346]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
—
—
—
—
0
9
219
2052
—
Fever
A03 [2002000144]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
—
0
9
222
2085
—
—
—
0
9
219
2052
—
Teeth/gum symptom/complaint
D19 [2002000318]
1.2e-01
—
—
—
—
—
7.3e-01
cases:2.25%
controls:2.01%
—
—
—
—
—
—
—
—
—
—
cases:3.37%
controls:1.65%
5
42
217
2052
—
—
—
—
—
7
32
201
1902
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
—
-1.0e+50
—
—
—
—
1.1e+00
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:2.88%
controls:0.98%
—
0
6
222
2088
—
—
—
—
6
19
202
1915
clarithromycin; oral, parenteral
J01FA09 [21602977]
1.9e-01
—
—
—
—
—
4.7e-01
cases:2.25%
controls:1.86%
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:2.43%
5
39
217
2055
—
—
—
—
—
8
47
200
1887
acrivastine; oral
R06AX18 [21603518]
3.5e-01
—
—
—
—
—
1.7e-01
cases:4.95%
controls:3.53%
—
—
—
—
—
—
—
—
—
—
cases:10.58%
controls:9.10%
11
74
211
2020
—
—
—
—
—
22
176
186
1758
Hyperlipidaemia, unspecified
E78.5 [45537986]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Thrombin time
3243-3 [3036489]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2087
—
—
—
—
—
—
dexamethasone
C05AA09 [21601613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
6.2e-01
1.2e+00
—
—
—
—
9.6e-01
cases:3.15%
controls:1.72%
cases:2.25%
controls:0.67%
—
—
—
—
—
—
—
—
cases:4.33%
controls:1.71%
7
36
215
2058
5
14
217
2080
—
—
—
—
9
33
199
1901
Therapeutic discussion
SPAT1240 [2001700341]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
11
219
2050
—
Physical Medicine And Rehabilitation
25 [38004468]
—
—
—
—
—
—
4.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:1.91%
—
—
—
—
—
—
6
37
202
1897
Audiometric test
21727005 [4071702]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
Other foetal and placental problems affecting management of mother, Excessive foetal growth[SIK YLIPAIN RASK KESTOON NÄHDEN, SYNNYTYKSEN AIKANA]
6566B [2000405206]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Diabetes mellitus in pregnancy, unspecified
O24.9 [45539107]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
0
17
208
1917
prednisolone
A07EA01 [21600653]
1.7e-01
—
—
—
—
8.3e-01
6.0e-01
cases:3.15%
controls:2.67%
—
—
—
—
—
—
—
—
cases:2.74%
controls:1.21%
cases:5.77%
controls:3.26%
7
56
215
2038
—
—
—
—
6
25
213
2036
12
63
196
1871
Rash localized
S06 [2002000971]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Gastroenteritis presumed infection
D73 [2002000371]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
222
2085
—
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
—
—
—
—
1.7e+00
8.8e-01
1.9e-01
—
—
—
—
—
—
—
—
cases:3.15%
controls:0.57%
cases:3.65%
controls:1.55%
cases:3.85%
controls:3.21%
—
—
—
—
7
12
215
2078
8
32
211
2029
8
62
200
1872
Other and unspecified convulsions
R56.8 [45602033]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
14
208
1920
Gastroenterology
10 [38004455]
1.0e+00
-1.0e+50
—
—
-1.0e+50
—
1.4e+00
cases:2.70%
controls:1.00%
cases:0.00%
controls:0.81%
—
—
—
—
cases:0.00%
controls:0.24%
—
—
cases:3.85%
controls:0.98%
6
21
216
2073
0
17
222
2077
—
—
0
5
222
2085
—
8
19
200
1915
Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma
32166-1 [3008714]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.44%
—
—
0
11
222
2083
0
9
222
2085
—
—
—
0
9
219
2052
—
pH of Urine
2756-5 [3015736]
4.1e-01
1.2e+00
—
—
—
—
4.2e-01
cases:2.70%
controls:1.81%
cases:2.70%
controls:0.86%
—
—
—
—
—
—
—
—
cases:4.33%
controls:2.90%
6
38
216
2056
6
18
216
2076
—
—
—
—
9
56
199
1878
estriol; oral, parenteral, vaginal
G03CA04 [21602518]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
10
208
1924
rubella, live attenuated
J07BJ01 [21601359]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
—
Excessive ear wax
H81 [2002000536]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
0
7
222
2087
0
6
222
2088
—
—
—
—
0
7
208
1927
Acute pericoronitis
K05.22 [2000502725]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
0
12
222
2082
0
6
222
2088
—
—
—
0
5
219
2056
—
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
3.2e-02
2.3e-01
—
—
—
—
-1.8e-02
cases:5.86%
controls:5.68%
cases:2.70%
controls:2.15%
—
—
—
—
—
—
—
—
cases:5.29%
controls:5.38%
13
119
209
1975
6
45
216
2049
—
—
—
—
11
104
197
1830
Vena saphena Magna and / or swarm of nodule and possible local emissions
5611 [2000100813]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
222
2084
—
—
—
—
—
—
Antenatal screening for malformation
717800004 [36713462]
1.2e-01
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-5.1e-01
cases:2.25%
controls:2.01%
cases:0.00%
controls:1.24%
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:1.02%
cases:2.88%
controls:4.71%
5
42
217
2052
0
26
222
2068
—
—
0
7
222
2083
0
21
219
2040
6
91
202
1843
Ventricular premature depolarization
I49.3 [45538386]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
0
7
208
1927
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Bacteria identified in Blood by Culture
600-7 [3023368]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
—
0
13
222
2081
—
—
—
—
—
short-acting sulfonamides - combinations
J01EB20 [21602943]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:2.53%
—
—
—
—
—
—
6
49
202
1885
Other single spontaneous delivery
O80.8 [45534307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
13
222
2081
—
—
—
—
—
0
8
208
1926
Placement of orthodontic arch wire
SJD10 [2001310438]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
—
carbamide, combinations
D02AE51 [21601976]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.86%
cases:0.00%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
0
39
222
2055
0
37
222
2057
—
—
—
—
—
Delayed and secondary postpartum haemorrhage
O72.2 [45597026]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Irrigation or wax removal of outer auditory canal
SPAT1033 [2001700134]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
10
208
1924
Fetal Trisomy 21 risk [Likelihood] Based on maternal age
49090-4 [3049207]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
—
0
5
222
2089
—
—
—
—
—
Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma
32046-5 [3021584]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:3.37%
controls:0.83%
—
0
7
222
2087
—
—
—
—
7
16
201
1918
Type 1 diabetes mellitus, With ketoacidosis
E10.1 [45542735]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2087
—
—
—
—
—
—
dextromethorphan, combinations; oral
N07XX59 [43534835]
—
—
—
—
—
—
1.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.88%
controls:2.53%
—
—
—
—
—
—
6
49
202
1885
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
8.8e-01
—
—
—
—
—
6.1e-02
cases:3.60%
controls:1.53%
—
—
—
—
—
—
—
—
—
—
cases:6.73%
controls:6.36%
8
32
214
2062
—
—
—
—
—
14
123
194
1811
sodium fluoride; oral
A01AA01 [21600005]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
0
7
222
2087
0
5
222
2089
—
—
—
—
0
6
208
1928
First trimester maternal screen panel - Serum or Plasma
48798-3 [3050129]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
6
222
2088
—
—
—
—
—
Besnier prurigo
L20.0 [45562534]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.76%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
0
16
222
2078
0
6
222
2088
—
—
—
0
6
219
2055
—
Contraceptive management
Z30 [45756073]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.24%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
0
5
222
2089
—
—
—
—
—
0
8
208
1926
pentoxyverine; oral, rectal
R05DB05 [21603414]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.31%
—
—
—
—
—
—
0
6
208
1928
Retrognaty, mandibular
K07.13 [2000502762]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Counselling and guidance which enhance independent living
R2130 [2001310196]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
0
7
222
2087
—
—
—
—
0
10
208
1924
Trachoma, unspecified[CHLAMYDIA ALIA DEFINITA SEU NUD]
0769X [2000400645]
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
cases:18.92%
controls:0.00%
—
—
—
—
—
—
—
—
—
42
0
180
2094
—
—
—
Intestinal infections due to other organisms, Other organism, not elsewhere classified
0088X [2000400186]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
11
222
2083
—
—
—
—
—
0
14
208
1920
Other obesity
E66.8 [45533036]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
0
5
208
1929
Hypertension complicating pregnancy, childbirth and the puerperium, Eclampsia[ECLAMPSIA , SYNNYTYKSEN AIKANA]
6426B [2000405039]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
222
2087
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
220
1642
1.73
6.86
11.4
9.5
0.00
0.00
e9/l
0.99
181
1356
130
847
1.78
6.49
3.8
2.6
0.44
0.40
e6/l
0.07
95
595
144
992
1.69
5.78
3.9
2.7
15.51
126.99
e6/l
1.13
110
747
104
671
1.73
5.23
3.2
2.3
10.64
8.28
e6/l
0.35
97
619
66
388
1.83
4.51
2.1
1.8
—
—
—
0
0
113
781
1.61
4.30
2.4
1.8
—
—
—
0
0
73
451
1.75
4.23
3.1
2.5
2.50
3.99
e6/l
0.75
26
197
150
1112
1.55
4.21
5.5
6.0
—
—
—
0
0
162
1225
1.53
4.14
4.7
3.2
53.58
66.85
e6/l
0.19
120
827
20
75
2.75
4.05
1.8
2.1
7.42
7.42
ph
0.20
20
75
15
48
3.20
3.97
1.9
2.0
1.54
2.61
mmol/l
—
9
37
15
48
3.20
3.97
1.9
2.0
9.39
9.15
kpa
0.22
15
48
15
48
3.20
3.97
1.9
2.0
4.67
5.05
kpa
2.22
15
48
138
1024
1.52
3.78
2.0
2.0
117.80
138.50
u/l
0.73
132
984
114
813
1.56
3.74
3.7
3.2
—
0.00
—
0
6
231
1917
1.46
3.56
4.1
3.2
0.00
0.01
estimate
0.80
52
357
56
341
1.74
3.41
10.2
7.4
104.25
104.65
mmol/l
0.28
56
341
7
10
7.10
3.37
1.9
1.1
—
—
—
0
0
226
1885
1.44
3.29
5.9
4.3
6.47
6.38
mmol/l
0.13
216
1783
231
1935
1.44
3.28
4.2
3.3
0.00
0.00
estimate
-0.00
52
358
232
1951
1.43
3.19
4.2
3.3
0.00
0.03
estimate
1.08
46
344
388
3646
2.02
3.12
16.2
12.5
139.60
139.82
mmol/l
1.25
382
3582
256
2197
1.43
3.11
5.5
3.8
72.60
89.35
e6/l
—
5
26
82
570
1.55
2.97
3.2
2.2
522.64
505.28
mosm/kgh2o
0.26
76
508
52
324
1.69
2.93
2.5
2.3
31.33
39.10
u/l
0.72
46
270
175
1420
1.40
2.84
6.6
4.5
36.52
37.08
g/l
0.61
168
1361
34
190
1.86
2.76
2.1
1.7
616.33
5437.57
u/l
—
9
66
19
85
2.29
2.74
3.9
2.7
1.33
1.90
index
—
9
38
387
3654
1.91
2.74
16.5
12.6
3.92
3.92
mmol/l
0.10
380
3580
139
1098
1.40
2.59
2.5
2.1
—
—
—
0
0
86
622
1.48
2.58
2.0
1.6
—
—
—
0
0
122
945
1.41
2.54
4.9
3.5
7.39
7.40
ph
0.50
86
646
61
411
1.57
2.53
1.8
1.6
—
—
—
0
0
9
26
3.51
2.49
1.8
1.5
89.32
92.23
%
—
9
26
187
1561
1.36
2.46
3.9
2.9
6.18
6.15
ph
0.13
99
953
19
90
2.16
2.42
5.4
1.6
—
—
—
0
0
9
27
3.38
2.40
2.9
1.3
—
—
—
0
0
63
433
1.54
2.40
1.7
1.3
—
—
—
0
0
336
3090
1.46
2.39
5.1
4.9
14.60
14.29
pmol/l
1.55
318
2933
88
650
1.45
2.37
1.6
1.6
435.76
30928271.74
pmol/l
1.06
80
582
30
171
1.81
2.32
8.0
8.6
25.11
25.04
mmol/l
0.05
30
171
58
395
1.54
2.31
3.2
2.1
29.71
29.52
s
0.07
58
385
72
515
1.48
2.28
1.3
1.4
32.49
32.45
iu/l
0.00
58
458
6
13
4.67
2.28
1.2
3.0
0.00
0.00
estimate
—
6
13
27
151
1.84
2.22
1.1
1.3
—
—
—
0
0
304
2762
1.38
2.19
10.7
7.5
78.92
76.16
u/l
0.61
294
2651
34
205
1.72
2.19
15.0
8.1
7.50
7.56
mmol/l
0.02
34
199
10
36
2.82
2.15
1.7
1.5
1.51
1.63
mmol/l
—
10
36
48
319
1.57
2.13
2.5
2.0
0.00
0.07
estimate
0.78
16
69
190
1617
1.32
2.10
3.2
2.5
—
—
estimate
—
0
0
125
1000
1.36
2.10
4.1
3.3
0.00
0.00
estimate
0.50
50
343
60
423
1.49
2.04
1.8
1.6
1301.51
1149.24
nmol/l
0.73
51
328
110
866
1.37
2.04
3.3
3.2
1.02
2.83
kg/l
0.50
66
557
5
11
4.59
1.94
5.8
2.6
0.52
0.62
mmol/l
—
5
11
163
1372
1.31
1.91
2.0
1.9
107.27
100.36
pmol/l
0.58
89
737
12
52
2.35
1.89
1.2
1.8
—
—
—
0
0
25
146
1.76
1.82
1.8
1.5
—
—
—
0
0
59
426
1.45
1.79
6.8
2.3
5.27
5.22
umol/l
0.02
48
365
93
728
1.36
1.78
4.6
3.9
—
—
—
0
0
382
3653
1.59
1.76
17.0
12.2
18.24
18.94
mg/l
0.19
328
2915
115
931
1.33
1.76
3.1
2.4
—
—
—
0
0
63
463
1.43
1.75
1.9
1.5
—
—
—
0
0
28
172
1.67
1.72
1.8
1.5
0.23
0.34
mg/l
0.66
16
75
217
1916
1.28
1.71
8.1
6.2
0.56
0.53
e9/l
1.10
193
1705
19
105
1.85
1.66
5.4
8.5
—
—
—
0
0
152
1289
1.28
1.64
7.7
8.3
1.06
1.08
inr
0.44
126
1059
5
14
3.60
1.62
4.4
2.3
0.60
0.50
index
—
5
14
78
603
1.36
1.62
3.9
2.4
129.39
89.88
ug/g
0.86
64
478
138
1165
1.28
1.53
3.6
2.8
23.44
91.72
ng/l
0.50
73
593
0
44
0.00
1.52
0.0
1.4
—
—
—
0
0
0
44
0.00
1.52
0.0
1.4
—
—
—
0
0
0
44
0.00
1.52
0.0
1.4
—
—
—
0
0
0
44
0.00
1.52
0.0
1.4
—
—
—
0
0
118
980
1.29
1.48
4.9
4.5
—
—
—
0
0
366
3491
1.42
1.48
6.1
5.8
1.68
1.78
mu/l
1.27
347
3343
108
887
1.29
1.48
2.1
1.7
1.47
0.83
mg/l
1.36
77
695
140
1189
1.27
1.47
8.3
6.1
—
—
—
0
0
215
1920
1.25
1.46
8.2
6.2
0.04
0.04
e9/l
0.27
191
1706
195
1723
1.25
1.45
2.7
2.5
75.48
76.61
nmol/l
0.22
184
1614
124
1039
1.28
1.45
5.0
2.9
7.81
7.79
mmol/l
0.02
108
898
5
16
3.15
1.44
2.0
1.4
—
—
—
0
0
26
165
1.61
1.44
2.8
2.3
0.00
0.02
estimate
0.49
12
59
14
74
1.92
1.40
1.1
1.1
3.56
6.91
u/ml
—
9
23
14
74
1.92
1.40
1.1
1.9
5.78
6.59
pmol/l
0.41
14
74
30
199
1.55
1.39
4.1
1.4
—
—
—
0
0
30
199
1.55
1.39
4.1
1.4
—
—
—
0
0
12
60
2.03
1.39
1.1
1.1
—
—
—
0
0
42
300
1.45
1.38
1.6
1.3
—
—
—
0
0
30
200
1.54
1.36
4.2
1.4
—
—
—
0
0
28
185
1.55
1.33
4.3
1.4
—
—
—
0
0
219
1974
1.23
1.32
8.1
6.2
1.98
1.97
e9/l
0.06
199
1789
161
1405
1.24
1.31
8.7
5.8
1.22
1.22
mmol/l
0.23
156
1300
31
212
1.50
1.27
1.1
1.1
—
—
—
0
0
237
2162
1.23
1.24
11.5
9.9
4.35
3.88
e9/l
1.18
213
1921
104
874
1.25
1.17
2.8
2.2
302.96
307.13
umol/l
0.21
95
817
35
250
1.44
1.17
1.2
1.1
—
114.00
—
0
5
19
118
1.64
1.17
2.2
1.9
—
—
—
0
0
220
2000
1.21
1.17
3.3
3.1
93.27
80.68
ug/l
0.83
215
1913
8
39
2.07
1.16
1.0
1.2
—
—
—
0
0
5
20
2.52
1.15
1.2
1.1
—
—
—
0
0
220
2004
1.21
1.13
8.4
6.8
0.20
0.18
e9/l
0.89
199
1800
27
384
0.68
1.12
1.8
1.9
—
—
—
0
0
397
3874
1.60
1.10
19.0
14.6
68.62
68.22
umol/l
0.18
392
3834
130
1131
1.22
1.06
3.3
2.5
—
0.00
—
0
15
31
221
1.44
1.06
1.2
1.2
—
—
—
0
0
100
848
1.24
1.04
1.7
1.6
17.77
20.70
nmol/l
1.67
93
753
24
163
1.50
1.04
1.7
2.2
—
—
—
0
0
114
981
1.22
1.03
2.8
2.8
—
—
—
0
0
175
1570
1.20
1.03
9.3
6.6
1.22
1.22
mmol/l
0.05
154
1359
28
389
0.70
1.03
1.3
1.3
258.87
152.96
u/ml
—
9
180
23
155
1.51
1.03
1.7
1.5
824.88
862.76
mu/l
0.11
14
128
14
83
1.71
1.02
2.2
1.9
—
—
—
0
0
9
48
1.89
1.01
1.0
1.1
—
—
—
0
0
35
258
1.39
1.01
4.4
3.2
—
—
—
0
0
27
190
1.45
0.99
3.6
2.8
74.17
75.36
e9/l
0.05
19
130
170
1526
1.19
0.99
3.9
3.0
0.00
0.05
estimate
1.98
41
296
9
49
1.85
0.99
1.9
1.8
16.17
17.18
%
—
9
49
65
528
1.27
0.98
1.2
1.2
—
—
—
0
0
9
50
1.82
0.97
1.7
1.6
—
—
—
0
0
9
52
1.75
0.93
2.2
2.2
—
—
—
0
0
106
917
1.21
0.91
4.3
3.7
9.41
7.35
mg/mmol
0.11
67
539
12
71
1.71
0.89
1.2
1.5
1.05
1.31
mm
—
5
51
191
1744
1.18
0.89
8.2
6.2
2.94
2.80
%
0.36
184
1662
104
900
1.21
0.89
1.8
1.4
2.01
2.14
g/l
0.43
67
608
10
56
1.81
0.88
1.4
1.5
—
59.90
—
0
6
8
43
1.88
0.87
1.0
1.2
—
—
—
0
0
8
43
1.88
0.87
2.5
1.8
—
—
—
0
0
21
145
1.47
0.86
17.6
11.8
93.10
93.28
%
0.05
21
145
115
1008
1.20
0.86
1.7
1.4
—
—
—
0
0
33
250
1.35
0.83
4.9
3.7
82.46
71.50
ng/l
0.25
28
226
12
73
1.66
0.82
1.3
1.5
—
—
—
0
0
33
251
1.34
0.81
5.5
3.3
5.85
5.79
kpa
0.16
33
246
0
25
0.00
0.79
0.0
1.2
—
2.08
—
0
20
30
226
1.35
0.79
15.3
7.8
1.34
1.17
mmol/l
0.39
30
221
27
200
1.37
0.78
4.5
1.4
—
—
—
0
0
104
912
1.19
0.77
4.0
3.1
40.95
37.99
mg/l
0.04
66
558
389
3807
1.36
0.75
13.2
10.7
—
—
—
0
0
9
54
1.68
0.75
1.1
1.3
—
—
—
0
0
5
24
2.10
0.74
1.8
1.4
—
—
—
0
0
18
125
1.46
0.74
1.2
1.1
—
—
—
0
0
14
92
1.54
0.73
6.4
4.1
320.00
209.53
mg/l
—
8
38
189
1747
1.15
0.72
8.4
6.3
0.68
0.71
%
0.30
181
1657
38
302
1.28
0.71
4.6
4.7
0.21
1.10
%
3.29
14
87
5
26
1.93
0.71
1.0
1.1
—
—
—
0
0
20
144
1.41
0.69
5.0
2.2
0.56
0.59
%
0.19
20
144
12
77
1.58
0.69
1.3
1.6
—
—
—
0
0
5
27
1.86
0.68
2.6
1.4
67.60
66.59
umol/l
—
5
27
188
1743
1.14
0.67
8.4
6.3
8.32
8.41
%
0.20
181
1667
37
296
1.27
0.66
5.0
5.1
0.00
0.23
%
0.94
11
69
26
198
1.33
0.66
1.5
2.2
2.22
8.54
iu/ml
—
5
46
192
1786
1.14
0.65
8.3
6.0
55.88
56.57
%
0.42
186
1727
20
146
1.39
0.65
5.0
2.2
1.65
1.16
%
1.10
20
146
150
1373
1.15
0.64
5.7
3.1
34.15
29.34
u/l
0.73
142
1318
116
1044
1.15
0.63
1.4
1.3
1.16
1.48
u/ml
0.24
43
310
32
254
1.28
0.62
5.3
3.4
7.38
7.39
ph
0.31
15
141
68
587
1.19
0.62
3.0
3.1
41.45
312.74
ng/l
1.18
44
346
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.6
—
146.24
—
0
21
356
3465
1.20
0.60
4.6
4.3
5.79
5.71
mmol/l
0.45
338
3303
193
1804
1.13
0.59
8.4
6.2
29.48
29.23
%
0.14
187
1742
22
286
0.76
0.59
1.2
1.2
—
—
—
0
0
393
3866
1.33
0.58
13.8
10.8
25.68
25.64
u/l
0.02
386
3798
27
213
1.29
0.55
19.0
9.5
—
—
—
0
0
348
3386
1.17
0.55
5.5
5.1
37.96
37.98
mmol/mol
0.02
333
3255
35
286
1.24
0.55
4.9
4.8
0.00
0.10
%
2.14
11
71
14
99
1.43
0.55
1.1
1.0
0.26
0.70
u/ml
—
5
38
35
287
1.24
0.53
4.6
4.6
0.04
0.80
%
4.39
13
81
9
62
1.46
0.53
1.1
1.0
—
—
—
0
0
19
247
0.76
0.52
1.0
1.1
1.60
1.60
g/l
0.03
19
247
18
136
1.34
0.50
1.3
1.1
—
—
—
0
0
15
110
1.38
0.49
1.1
1.2
—
—
—
0
0
89
801
1.14
0.49
2.7
2.1
2.96
2.66
mg/l
0.67
80
692
73
651
1.15
0.46
1.5
1.4
511.11
527.30
titre
0.05
18
148
23
285
0.80
0.45
1.1
1.1
—
—
—
0
0
10
69
1.46
0.44
3.2
4.0
3.37
4.41
e9/l
—
10
69
40
341
1.19
0.44
1.3
1.2
—
—
—
0
0
5
31
1.62
0.43
1.2
1.2
—
—
—
0
0
5
32
1.57
0.42
1.0
3.1
—
—
—
0
0
174
1643
1.10
0.42
2.3
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
25.21
—
0
15
0
18
0.00
0.40
0.0
1.8
—
90.61
—
0
18
14
106
1.33
0.39
1.1
1.0
3.03
3.46
u/ml
—
7
45
12
89
1.36
0.38
2.8
4.0
50.08
58.66
%
1.85
12
89
10
135
0.73
0.37
3.3
2.2
4.00
4.28
iu/l
—
5
64
5
78
0.64
0.36
1.0
1.2
—
—
—
0
0
6
43
1.40
0.35
2.3
1.7
6.45
4.99
u/ml
—
6
43
123
1152
1.10
0.35
3.5
2.6
0.00
0.02
estimate
1.47
40
286
21
172
1.23
0.35
2.4
2.2
2.73
4.54
ug/l
1.00
21
152
51
454
1.14
0.35
1.6
1.4
—
—
—
0
0
36
312
1.17
0.34
2.0
2.3
29.02
19.95
au/ml
—
5
38
13
100
1.31
0.34
6.4
3.8
23.02
25.18
mmol/l
2.11
13
95
6
46
1.31
0.33
1.0
1.3
—
—
—
0
0
12
92
1.31
0.32
3.1
2.3
24.10
24.54
mmol/l
0.15
12
92
31
270
1.16
0.29
12.4
10.4
0.10
1.02
mmol/l
0.64
24
220
7
57
1.23
0.29
1.6
1.4
—
—
—
0
0
14
112
1.26
0.28
1.1
1.1
—
—
—
0
0
14
112
1.26
0.28
1.1
1.1
—
—
—
0
0
14
112
1.26
0.28
1.4
1.3
—
—
—
0
0
8
62
1.30
0.28
5.9
4.2
31.03
30.46
mg/l
—
8
56
8
62
1.30
0.28
5.9
4.2
34.06
22.50
mg/l
—
8
54
31
272
1.15
0.27
12.4
10.5
7.41
7.41
ph
0.09
15
156
287
2804
1.08
0.26
4.5
3.2
51.26
39.08
u/l
0.63
272
2722
34
302
1.14
0.25
1.9
1.7
5.98
6.10
ph
0.30
25
170
32
283
1.14
0.25
1.1
1.3
—
36.83
—
0
23
129
1228
1.07
0.25
3.3
3.4
2.36
2.35
mmol/l
0.14
122
1147
69
640
1.09
0.25
2.6
2.4
2.45
2.43
mmol/l
0.98
62
585
40
443
0.89
0.25
1.3
1.4
—
—
—
0
0
10
126
0.79
0.24
1.3
8.3
—
—
—
0
0
18
152
1.19
0.24
2.2
1.9
—
—
—
0
0
5
42
1.19
0.21
1.2
1.3
—
—
—
0
0
154
1598
0.94
0.21
2.0
1.9
1.52
1.38
mmol/l
0.97
139
1419
0
10
0.00
0.21
0.0
1.0
—
5.80
—
0
10
0
12
0.00
0.21
0.0
1.2
—
1.21
—
0
12
0
13
0.00
0.21
0.0
2.7
—
1.15
—
0
13
0
13
0.00
0.21
0.0
1.1
—
0.02
—
0
13
22
250
0.87
0.20
1.5
1.1
0.88
0.92
g/l
0.35
22
250
15
127
1.19
0.20
1.1
1.1
3.01
2.08
u/ml
—
7
69
6
51
1.18
0.19
1.0
1.1
—
—
—
0
0
14
118
1.19
0.19
1.6
1.3
15.10
14.96
u/l
0.01
14
95
6
53
1.13
0.18
2.0
1.4
422.33
449.06
pmol/l
—
6
47
354
3501
1.08
0.18
4.0
4.0
1.34
1.26
mmol/l
0.94
343
3348
7
62
1.13
0.17
2.1
2.5
—
—
—
0
0
90
859
1.06
0.17
1.4
1.3
2.80
12.67
u/ml
3.13
47
368
67
633
1.07
0.17
1.7
1.4
—
—
—
0
0
20
178
1.13
0.15
1.3
1.4
183.40
221.46
miu/ml
—
10
90
9
80
1.13
0.15
1.2
1.1
—
—
—
0
0
32
295
1.09
0.14
2.0
1.4
—
—
—
0
0
12
137
0.87
0.12
1.8
1.7
—
—
—
0
0
46
486
0.94
0.12
1.7
1.8
3.63
3.50
mmol/l
0.29
29
354
11
95
1.16
0.11
10.0
3.0
1.62
1.24
mg/l
1.50
11
89
371
3687
1.06
0.10
4.8
4.7
4.94
4.93
mmol/l
0.16
362
3557
370
3679
1.05
0.09
4.7
4.6
1.52
1.54
mmol/l
0.43
360
3531
96
934
1.04
0.09
1.4
1.4
15.81
24.69
iu/ml
1.33
32
302
6
58
1.03
0.08
14.0
3.0
46.67
30.06
umol/l
—
6
53
7
65
1.08
0.08
1.1
1.1
—
—
—
0
0
7
67
1.05
0.08
1.1
1.2
—
—
—
0
0
9
86
1.05
0.07
1.2
1.7
—
—
—
0
0
400
4012
0.91
0.07
24.3
19.1
6.82
6.51
e9/l
2.52
394
3950
14
128
1.10
0.07
7.7
3.7
—
—
—
0
0
400
4012
0.91
0.07
24.1
19.0
4.49
4.50
e12/l
0.25
395
3955
30
315
0.95
0.06
2.0
2.4
64.69
34.94
u/ml
0.39
30
300
16
148
1.08
0.06
1.4
1.3
—
—
—
0
0
16
149
1.08
0.05
1.3
1.9
0.21
0.24
g/l
1.30
16
143
370
3713
0.97
0.04
5.4
5.1
2.94
2.94
mmol/l
0.03
358
3570
10
91
1.10
0.04
1.2
1.1
3.04
2.07
eliau/ml
—
5
50
400
4009
0.93
0.03
24.2
19.1
273.31
266.14
e9/l
1.52
395
3956
10
108
0.92
0.03
1.3
1.3
354.80
473.53
mg/l
—
10
103
182
1833
0.99
0.03
3.0
2.8
—
—
—
0
0
19
182
1.05
0.02
6.3
3.4
4.93
5.16
kpa
0.86
19
177
47
461
1.02
0.02
2.1
2.0
—
—
—
0
0
54
532
1.02
0.01
1.4
1.2
—
—
—
0
0
14
137
1.02
0.00
1.5
1.3
—
—
—
0
0
16
155
1.03
0.00
1.3
1.8
1.11
1.22
g/l
1.16
16
147
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
0.03
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
47.00
—
0
5
5
58
0.86
-0.00
1.2
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
7.8
—
4.58
—
0
6
7
74
0.95
-0.00
1.7
2.1
4.64
5.76
mmol/24h
—
7
62
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
1.16
—
0
5
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
328.17
—
0
6
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
6.76
—
0
5
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: AB1_CHLAMY_OTHER – Diseases caused by chlamydiae

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).